What does the science say about Marietta Weight Loss with Semaglutide
The SUSTAIN 6 trial, published in The NEJM in 2016, showed that semaglutide was more effective than placebo at lowering A1c (HbA1c) levels and overall body weight in people with type 2 diabetes.
The PIONEER 6 trial, published in The Lancet in 2018, showed that semaglutide was better than sitagliptin at controlling blood sugar and lowering total body weight for daibetics.
The PIONEER 3 trial, published in the Journal of the American Medical Association in 2019, found that semaglutide outperformed the placebo group at lowering HbA1c levels and body weight in T2diabetics who had not been able to control their blood sugar with metformin alone.
The PIONEER 4 trial, published in Diabetes Care in 2019, showed semaglutide was better than the drug liraglutide at lowering HbA1c levels and total body weight in type 2 diabetics who had been unable to manage their blood sugar with metformin and sulfonylurea.
The PIONEER 5 trial, published in The Lancet Diabetes & Endocrinology in 2020, found that semaglutide out performed the placebo group at lowering HbA1c levels and body weight in people who had type 2 diabetes who had not been able to control their blood sugar with insulin by itself.









